MedTrace Logo

Evaluation of a Specific Transdermal Cannabidiol Product for Chronic Musculoskeletal Joint Pain.

NCT05002114 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2022-07-06

No results posted yet for this study

Summary

Double-blind, randomized into two arms (TC and TP): patients get either topical cannabidiol or topical placebo up to three times daily. Inclusion criteria will be chronic joint pain with intent to treat or currently treated with opioids. Exclusion criteria will include current cannabis use, severe medical illness or lacking in capacity to be involved in study. TC and TP will be prescribed for use TID in predefined dosages and quantities.

Conditions

  • Musculoskeletal Joint Pain

Interventions

DRUG

Cannabidiol

Topical CBD cream - special formulation

OTHER

Placebo

Not the drug

Sponsors & Collaborators

  • Louisiana State University Health Sciences Center Shreveport

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-31
Primary Completion
2023-01-31
Completion
2023-01-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05002114 on ClinicalTrials.gov